Montag, 27.04.2026, Calendar Week 18, 117. day of the year, 248 days remaining until EoY.

Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.

Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US6294441000

Filter zurücksetzen

Do you already know our new terminal view? Click here.

FIGI: -

NRXP

NRx Pharmaceuticals, Inc.

GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH

NAME

NRx Pharmaceuticals, Inc.

ISIN

US6294441000

TICKER

NRXP

MIC

XNAS

REUTERS

NRXP.OQ

BLOOMBERG

NRXP US

Do., 06.02.2025 NRx Pharmaceuticals

Newsfeed

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 | NRx Pharmaceuticals, Inc.

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc. | NRx Pharmaceuticals, Inc.

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market | NRx Pharmaceuticals, Inc.

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th A | NRx Pharmaceuticals, Inc.

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations | NRx Pharmaceuticals, Inc.

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics | NRx Pharmaceuticals, Inc.

HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025 | NRx Pharmaceuticals, Inc.

Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials" | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 | NRx Pharmaceuticals, Inc.

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 | NRx Pharmaceuticals, Inc.

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024 | NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds | NRx Pharmaceuticals, Inc.

Final Deadline Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.

NRXP Monday Deadline: ROSEN, A Top Ranked Law Firm, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - NRXP, NRXPW | NRx Pharmaceuticals, Inc.

Deadline Monday Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.

NRXP FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW | NRx Pharmaceuticals, Inc.

Deadline Monday Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.

NRXP FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW | NRx Pharmaceuticals, Inc.

Deadline Monday Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.

NRXP FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW | NRx Pharmaceuticals, Inc.

Monday Deadline Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.

DEADLINE NEXT WEEK: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW | NRx Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NRx Pharmaceuticals, Inc, of Class Action Lawsuit and Upcoming Deadline - NRXP; NRXPW | NRx Pharmaceuticals, Inc.

ROSEN, A TOP RANKED LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW | NRx Pharmaceuticals, Inc.

7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.

(NRXP; NRXPW) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading NRx Pharmaceuticals Class Action Lawsuit | NRx Pharmaceuticals, Inc.

ROSEN, A TOP RANKED LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPW | NRx Pharmaceuticals, Inc.

ROSEN, LEADING INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPW | NRx Pharmaceuticals, Inc.

NRX INVESTOR NEWS: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSE, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPW | NRx Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NRx Pharmaceuticals, Inc, of Class Action Lawsuit and Upcoming Deadline - NRXP; NRXPW | NRx Pharmaceuticals, Inc.

Shareholder Action Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.

Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NRx Pharmaceuticals, Inc, of Class Action Lawsuit and Upcoming Deadline - NRXP; NRXPW | NRx Pharmaceuticals, Inc.

Shareholder Action Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.

Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm | NRx Pharmaceuticals, Inc.